Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease

Background: Biomarker normalization and endoscopic remission are superior to clinical remission in achieving improved long-term clinical outcomes in patients with inflammatory bowel diseases. Goal: To study whether higher maintenance adalimumab levels are associated with clinical remission, biomarker normalization, and endoscopic remission. Study: Data were collected retrospectively from the patients’ medical records. We defined clinical remission as a Harvey Bradshaw Index ≤5 or a partial Mayo score ≤2 for Crohn’s disease (CD) and ulcerative colitis (UC), respectively, biomarker normalization as a C-reactive protein
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: Alimentary Tract: Original Articles Source Type: research